Purpose To estimate of drug resistances of (MBT) at patients with combination of tuberculosis and the HIV (TB+HIV).
Materials and Methods Patients with confection treated in tubercular hospital N02 for the period of 2005–2011
Results For the specified period the among patients with TB+HIV the share of low immune status (less than 200 cell/mkl), causing severe TB has increased from 32.5% up to 60.4%. It was accompanied by growth generalised forms of TB from 30.1% up to 56.5%.
MBT excreting it has been identified at 67.7% TB+HIV cases, and in 53.2% cases baccilar TB have been revealed by culture. From them only at 19.9% of MBT were sensitive to antitubercular drugs, at others tests identified presence of resistance of various prevalence. Resistance to streptomycin (73.2%) and izoniasid 73.4% was more often, it is a little bit less - to rifampicin - than 63.3%, and ethambutol - 41.2%. Among second line TB drugs the greatest resistance has been fixed to canamycin - 36.7%, to other drugs of this group it did not exceed 20%.
The proportion of patients with multi drug resistant MBT has determined in an interval of 80.6% of - 65.3%; among patients with new cases of TB it was on the average 73.3%. Extremely drug resistant MBT (XDR) has registered among for the new cases within 7.9% - 14.8%. Patients with XDR had expressed immune suppression and progressing of tuberculosis with development generalised forms even at use of ART. Lethal outcomes at them made 56.9%.
Conclusion wide circulation of multi and extremely drug resistant MBT at patients with TB+HIV makes inefficient treatment at prescription of f standard TB schemes. Besides for these patients use of methods of fast identification of drug resistance is necessary.
- Drug resistance
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.